Let our seasoned team of experts help you to succeed in the development and commercialization of your Cell and Gene Therapy, Biologics, Antibodies, ADCs or Biosimilars | Pharmefex Biologics, Cell & Gene Therapy Consulting Request Consultation Services Products Product, Process & Analytical Development Read More Quality And Regulatory Read More Manufacturing Strategy & Operations Read More Risk Management Read More Outsourcing and Supply Chain Management Read More Program Management Read More Recombinant Proteins Biosimilars Cell Therapy Gene Therapy Antibodies, Antibody Fragments, ADC Why Choose Pharmefex? Founded in 2014, Pharmefex provides expert technical, regulatory, and compliance services for cell and gene therapies, biologics, antibodies, ADCs, biosimilars, virology, and non-viral gene delivery. With decades of experience, we offer integrated CMC solutions to help your products move efficiently from discovery to market with less risk and cost. We have a proven track record in CMC development, regulatory submissions, technology transfers, and virology. Our low overhead keeps services affordable and competitive without compromising quality. We offer flexible, personalized support tailored to your specific needs. Most of our business comes from client referrals, a testament to our reliability and results. Partner with Pharmefex for reliable, expert-driven CMC solutions that accelerate your product’s success. Meet Our Consultants As consultants we bring together innovative minds to address critical challenges in biopharmaceutical development, manufacturing, regulatory strategy, and commercialization. We provide functional outsourcing and collaboration with expert knowledge, ensuring quality and compliance to optimize the journey from concept to patient care. Together, we aim to shape the future of biologics and advanced cell & gene therapies to improve outcomes for patients worldwide. Our Team

< Back FDA Endorses Shift Toward Non-Animal Testing. A Transformative Step in Drug Development Apr 30, 2025 FDA Endorses Shift Toward Non-Animal Testing: A Transformative Step in Drug Development The U.S. Food and Drug Administration (FDA) has announced a significant move to phase out the requirement for animal testing in certain preclinical contexts—beginning with monoclonal antibodies (mAbs). This decision marks a paradigm shift in regulatory science, as the FDA formally endorses New Approach Methodologies (NAMs) that include artificial intelligence (AI), organ-on-a-chip technologies, and advanced in vitro models to generate human-relevant data for safety evaluation. 📄 FDA Press Release 📘 FDA’s Roadmap: Reducing Animal Testing in Preclinical Safety Studies (PDF) A Scientific and Strategic Turning Point For decades, animal testing has served as a foundational element in drug development. Yet, the translational gap remains substantial: more than 90% of drug candidates that demonstrate efficacy and safety in animal models ultimately fail in human clinical trials. Recognizing this limitation, the FDA’s initiative promotes the use of scientifically advanced and human-relevant models that may provide better predictability for clinical outcomes. Key NAMs supported by the agency include: AI-Driven Computational Modeling – Simulating human biology, toxicity, and pharmacokinetics using complex datasets. Organ-on-a-Chip Technology – Microengineered devices that replicate the structure and function of human tissues. High-Throughput In Vitro Assays – Utilizing human cells and tissues to assess safety and efficacy more directly. This approach not only reduces reliance on animal models but is expected to accelerate early-stage development and enhance the quality of data supporting regulatory submissions. Therapeutic Relevance & Takeaways The FDA’s updated approach is particularly relevant for biologics with well-characterized mechanisms and safety profiles. Monoclonal antibodies are the immediate focus, but the implications extend to biosimilars, fusion proteins, recombinant enzymes, and potentially cell and gene therapies as scientific confidence in non-animal models grows. This transition offers significant benefits: shorter timelines, reduced preclinical costs, and more human-relevant data—all while addressing ethical concerns related to animal use. It also positions developers for greater global regulatory alignment, enabling data reuse and minimizing duplicative testing across jurisdictions. A key enabler of this shift is artificial intelligence . AI-driven modeling and analytics allow researchers to simulate human pharmacology, predict toxicity, and refine dose selection earlier in development. These capabilities not only improve preclinical decision-making but also reduce reliance on slower, less predictive in vivo models. As AI becomes further integrated into regulatory science, its use will be instrumental in enhancing translational accuracy, de-risking development, and meeting emerging FDA expectations for modernized evidence. Pharmefex: Strategic Guidance for a Changing Landscape Pharmefex Consulting is a top outsourcing company with deep regulatory and CMC expertise, uniquely positioned to support clients through this critical transition. With decades of experience across biologics, monoclonal antibodies, biosimilars, and advanced therapies, we help drug development teams navigate complex regulatory changes with confidence and efficiency. As a trusted provider of regulatory outsourcing services and CMC strategy consulting, we support clients in: Updating IND Strategies : Integrating NAMs, AI-based tools, and in vitro systems into preclinical packages while maintaining regulatory rigor and alignment with FDA expectations. Adapting BLA Planning : Structuring compelling, human-relevant data packages and evidence-based narratives that reflect evolving FDA guidance and leverage global regulatory precedents. Maintaining Efficiency and Compliance : Supporting global regulatory pathway planning, submission management, and operational execution without compromising quality. We also help biotech and pharmaceutical companies adjust their IND and BLA regulatory roadmaps to incorporate non-animal data, optimize development timelines, and reduce resource strain. Whether your team requires regulatory document authoring, FDA engagement strategy, or cross-functional CMC planning, Pharmefex delivers scalable, outsourced solutions tailored to your needs. With a proven track record supporting over 17 regulatory submissions and 5 commercial approvals, Pharmefex continues to serve as a reliable partner for efficient regulatory consulting, development acceleration, and strategic outsourcing support. 📩 To learn how Pharmefex, a leading life sciences consulting and outsourcing company, can optimize your preclinical and regulatory strategies in light of these changes, contact us at info@pharmefex.com or visit www.pharmefex.com . Previous Next

Regardless of your need in product areas including therapeutic proteins, monoclonal antibodies, biosimilars, or cell therapies, our broad range of services can help enhance your company's value every step of the way from early stage development to approval, launch and commercialization. Request for Consultation First name Last name Title Company Email Code Phone Street Address Street Address Line 2 City Region/State/Province Postal / Zip code Country Brief reason for enquiry Please provide further details about your request Timeframe for request Where did you hear about us? Submit Thanks for submitting!

< Back Why Including Pregnant Women in Clinical Trials Is Essential for Ethical and Effective Drug Development Jun 12, 2025 Introduction Pregnant and breastfeeding individuals have long been excluded from clinical research—an exclusion rooted in historical ethical concerns and perceived risk. Yet this protective stance has unintentionally led to a dangerous information gap: most drugs on the market lack sufficient data to guide safe and effective use during pregnancy or lactation. The newly released ICH E21 guideline offers a framework to change this. It aims to standardize global efforts to include and retain pregnant and breastfeeding participants in clinical trials when scientifically and ethically appropriate—supporting more equitable, evidence-based care. What’s Missing in Current Clinical Research Today, most clinical trials exclude pregnant individuals outright, even when the drug in question is likely to be used by this population after approval. As a result: Over 90% of medications approved in the U.S. between 2000 and 2010 lack pregnancy-specific safety data. Drug labels often provide warnings but little actionable guidance for clinicians treating pregnant patients. Dosing regimens are rarely optimized for pregnancy , despite known physiological changes that alter how drugs are processed in the body. Post-marketing surveillance systems are inconsistent and underutilized , limiting the ability to gather real-world safety data. This lack of evidence contributes to unnecessary risk, conservative treatment decisions, and missed opportunities for intervention—especially in chronic, infectious, and life-threatening conditions where medication use during pregnancy is unavoidable. What the ICH E21 Guideline Recommends ICH E21 outlines a science-based, ethically grounded approach to improving inclusion of pregnant and breastfeeding people in clinical development. The guideline recommends: Evaluating whether inclusion is scientifically appropriate as early as possible in the development lifecycle. Replacing automatic exclusion with careful, dynamic risk-benefit assessments based on available data and the potential for therapeutic use in pregnancy. Designing trials that include appropriate safety monitoring and tailored consent processes. Using supplemental data sources , including registries, modeling, and post-marketing surveillance to strengthen findings. Promoting regulatory harmonization across regions to support global alignment in ethics and expectations. This shift moves the industry away from blanket exclusion and toward a more thoughtful, transparent standard that protects participants while enabling better data generation. The Role of Biopharma and Clinical Teams Implementing ICH E21 will require collaboration across the drug development ecosystem. Biopharmaceutical sponsors, CROs, and site investigators must work together to evaluate when and how to include pregnant individuals, develop appropriate protocols, and align with ethics boards and regulators on safe participation. This guidance also has strategic implications. As regulators move toward global alignment on inclusion standards, companies that proactively address these expectations will be better positioned for smoother approvals, stronger safety data, and broader access post-launch. Conclusion The historical exclusion of pregnant and breastfeeding individuals from clinical trials has left a significant evidence gap in how we treat one of the most medically vulnerable populations. The ICH E21 guideline marks a necessary turning point—one that prioritizes equity, scientific rigor, and ethical responsibility. At Pharmefex, we support our clients in adapting to evolving regulatory landscapes like ICH E21 through strategic guidance, regulatory insight, and cross-functional compliance planning. Together, we can drive a more inclusive and evidence-informed future for drug development. Previous Next

Pharmefex serves clients that include pharmaceutical and biotechnology companies worldwide. In particular, we specialize in assisting companies to accelerate the development and approval of recombinant proteins and cellular and immunotherapy products. Our Clients Pharmefex partners with pharmaceutical and biotechnology companies worldwide, helping them accelerate the development and regulatory approval of recombinant proteins, cellular therapies, and immunotherapy products. Our clients range from innovative start-ups to global corporations. Over the past decade, we have successfully supported more than 128 clients across the globe, contributing to over 17 regulatory submissions and securing 5 commercial approvals. Renowned for delivering high-quality results across diverse markets, Pharmefex specializes in Chemistry, Manufacturing, and Controls (CMC) support while offering deep expertise in key areas critical to product development and regulatory success. Early Stage Support Process and analytical method development consulting CMO Selection & Oversight CMC Strategy Development RFP generation for CRO/CDMO selection Transfer from academic labs to CMOs Technical/CMC guidance Project/program management Outsourcing Risk assessments Phase Appropriate Quality Systems, investigations and quality audits Statistical design and analysis Late Stage Support Inspection Preparation and Management Compliance audits, gap assessments and remediation QA, QC, Qualification & Validation Technology transfer, scale-up & manufacturing Regulatory documents (IND, BLA, & other protocols) authoring and submission Product and process characterization study design Process and method validation Product comparability Quality by Design

Pharmefex consulting, founded in 2014, focuses on technical and CMC related consulting for cell therapy, recombinant proteins and biosimilars About Pharmefex Founded in 2014 in Bellevue Washington, Pharmefex Consulting provides expert technical, regulatory, and compliance services to clients around the world. Through a multidisciplinary approach, Pharmefex helps organizations to streamline product development, accelerate time to market, reduce cost of goods, and prevent and resolve compliance problems for recombinant proteins, and cellular immunotherapy products. The company deploys decades of experience to deliver top-quality results for a diverse base of global clients, including pharmaceutical and biotechnology companies and the law firms that serve them. Our hands on experience with commercialization and commercial production of Cellular Immunotherapy products sets us apart from others. We specialize in helping cell therapy and immunotherapy companies seamlessly accelerate their products to market and achieve higher profitability and to avoid costly mistakes in this quickly emerging field. Our Clients Our Team

Contact Pharmefex for pharmaceutical manufacturing outsourcing, CMC and technical Support of Your Biologics or Cell & Gene Therapy Product Phone: 425-818-1046 Email: info@pharmefex.com Address: Bellevue, Wa 98006

Support for Cell & Gene Therapy, Biosimilars, ADCs, Antibodies and Recombinant Proteins offered by Pharmefex. Products We Support Our consultants have the breadth and depth of experience to support a wide range of products to suit your needs. Contact us today to learn what we can do for you. Monoclonal Antibodies, Fragments, or ADCs Development of antibodies to target specific receptors as a means of controlling biological pathways has become increasingly more common as a therapeutic avenue for managing various diseases. Whether you are developing an antibody (IgG1, 2, 3, or 4) or antibody fragment to directly treat an indication, or are using an ADC to deliver an agent, we have the know how to help you navigate from start to finish in the fastest and most efficient manner. Cell and Gene Therapy Products, Viral Vectors The number of cell and gene therapy products in development continues to grow. These products offer tremendous promise for the treatment of grievous illness, yet each type of product presents unique challenges. We have hands on experience with multitude of cell and gene therapy products and have dealt with and solved the problems many developers don't yet know they have. Put our experience to work for you and avoid the costly mistakes and delayed timelines. Recombinant Proteins With decades of combined experience in the development, transfer and commercialization of protein based therapeutics, we can help you with all your needs. We have the expertise to support you from early stage discovery and expression vector design, creating relevant animal models, PK/PD and tox, through the latter stages of scale up, technology transfer, GMP manufacture, validation, and risk assessments, all the way through to your regulatory filings. Biosimilars Recent changes in the regulations have made development and commercialization of biosimilars a practical reality. We are now starting to see approval of these products in various markets. Yet too often the complexities of the development of biosimilars are underestimated, causing significantly increased costs and delays. How do you take advantage of the accelerated pathway to approval? Let us assist you in getting it right the first time.

Cell Therapy, Gene Editing, Vaccines, Viral Vectors, Analytical development, Method Qualification, Method Validation < Back Kuldip Sra, Ph.D. Sr. Consultant Dr. Kuldip Sra has over 30 years of experience of working in Biotech and Biopharma companies. Over his extended experience, Dr. Sra has worked on CMC product developments for Vaccines, C&G Therapy, Crispr Gene editing, Mabs and Vectors. During his career, he has worked on commercialization of 5 approved drugs and worked on over 15 INDs/IMPDs submissions. He has written CMC sections for briefing documents, INDs, BLA, CTAs, and has written responses and justifications to Regulatory agencies’ inquiries. Most recently Kuldip served as Executive Director of Late-Stage Development at Crispr Therapeutics where he led both analytical and Quality control functions for allogenic and autologous clinical drug products (in C&G products, Hematology, RegenMed modalities). Prior to Crispr, he was QC Director at Kite managing clinical lot release & raw material testing and environmental monitoring groups. At Kite, Dr. Sra worked on Kite’s two commercial products: Yescarta and Tecartus. His contributions were critical to significantly reducing QC release from 6 weeks to < 1 week (reduction of >80% in time of release). Kuldip worked for 15 years in Aviron/MedImmune/AstraZeneca in various capacities. He was involved in commercialization of three vaccine drug products and has designed and executed product comparability protocol for Vaccine drug products manufactured in Europe and in the US. He obtained an MS and PhD degrees in Biochemistry from Seton Hall University in Biochemistry and B.Sc . with Honors from Panjab University, India. Contact

Formulation Development, Drug Product Development, High Throughput Screening, High concentration/viscosity, Co-formulation, Viral Vectors < Back Bruce Kerwin, Ph.D. Prin. Consultant Dr. Kerwin has 30 years of leadership experience in industry developing drug products for biologics. He is a recognized expert in protein formulation and drug product design. During his career he has developed formulations and designed development strategies for multiple products from pre-clinical to commercial including Kineret, Aranesp and Imlygic. Bruce was formerly a Scientific Director at Amgen, VP of Drug Product Design at Just-Evotec Biologics and SVP of Process and Product Development at Umoja. He has led numerous drug product development teams and scientific research teams developing novel solutions to formulation problems such as high viscosity, high concentration, co-formulation of proteins, protein aggregation and formulation of viruses for subcutaneous, intravenous, intrathecal intravitreal and device delivery technologies. Work on large and small volume parenteral formulations included recombinant hemoglobin, cytokines, monoclonal antibodies, antibody drug conjugates, PEGylated proteins, glycosylated and non-glycosylated proteins, oncolytic viruses and lentivirus. As an integral member of multiple product teams he has also written drug product sections for multiple regulatory documents, participated in writing FDA pre-meeting documents and in-person FDA meetings. Bruce received his Ph.D. at the University of California at Davis followed by a Postdoctoral Fellowship at Washington State University. He has over 60 scientific publications, 14 patents and multiple invited lectures at international scientific conferences. He is currently a Scientific Advisor for Coriolis Pharma and a member of the editorial advisory board for the Journal of Pharmaceutical Science. Contact

Cell Therapy, Product Development, Risk Assessment, Regulatory Submissions, Project Management < Back Steve D. Hughes, Ph.D. Sr. Consultant Dr. Hughes has over 21 years of experience in biopharmaceutical and cellular therapy product development, ranging across multiple disciplines of manufacturing, research and development. From his most recent experience leading the process development team at Dendreon, he has extensive experience in development of cellular therapeutic products, and in supporting commercial phase production using risk assessment methodology and experimental models to evaluate potential process changes or improvements. Dr. Hughes’ experience also includes pharmacology, toxicology and project management/leadership. His pharma career began at Zymogenetics, where he started in early-stage research followed by a series of roles in pharmacology, toxicology and product development teams. Dr. Hughes then began work at Dendreon in 2010, where he led a cellular therapy product development team and managed early-stage development projects. He then took the role of leading the team responsible for support and innovation of the manufacturing process for Dendreon’s Autologous Cellular Immunotherapy product Provenge™, an activated cell therapy approved to treat metastatic prostate cancer. In this role, he directed a number of initiatives aimed at improving manufacturing process performance, including adaptation of closed system processing solutions, investigation and resolution of process yield trends, and continuous improvement initiatives such as streamlining process monitoring operations. Dr. Hughes holds a Ph.D in Biochemistry from the University of Texas Southwestern Medical Center in Dallas, TX and was a Postdoctoral Fellow at Lawrence Berkeley National Laboratory Life Sciences Division and Human Genome Center in Berkeley, CA. Contact

Clinical Development, Pharmacovigilance, Clinical Safety, Medical Affairs, Business Development, Licensing < Back Klaus Beck, MD/Ph.D. Prin. Consultant Klaus is a physician and scientist with 30 years of industry experience, in roles with increasing leadership responsibility in the US, Japan and the Asia-Pacific Region as well as Europe, Middle East and Africa – working across the R&D commercialization spectrum, spanning from discovery, translational and clinical research to launch, medical affairs and maintenance, plus global business development and licensing. Klaus worked at Genentech, Amgen, Elan, AstraZeneca and Merck & Co in local, regional and global roles. Klaus’ most recent full-time role was as Chief Medical Officer and Senior Vice President for Organon & Co (a women’s health-focused company, spun out of Merck & Co) where he had direct organizational responsibility for Global Clinical Development and Pharmacovigilance & Clinical Safety Science. Klaus led or was a key contributor to the creation of all corporate governance processes and review bodies at Organon and served as co-chair on two strategic priority Franchise teams, i.e. Women’s Health and Fertility and he chaired the R&D Review Committee, i.e. the most senior technical/medical decision-making body within Organon. Klaus has extensive product commercialization experience, having supported the launch and maintenance of several new products in the US and Japan. He has successfully led international teams (up to 850 colleagues) with a budget of up to $250MM and he has overseen (and in most cases initiated) extensive organizational change initiatives including building large cross-functional teams (from initiation to 350 staff) as well as significantly downsizing and reorienting existing teams. He has successful crisis management experience during the COVID-19 pandemic as Europe, Middle East, Africa and Canada Medical Affairs lead for Merck & Co and as Japan R&D Lead at AstraZeneca KK during and following the Tohoku/Fukushima Daiichi disaster. Klaus holds MD/PhD degrees (“Approbation als Arzt” in Germany; PhD in pharmacology) from the University of Heidelberg, Germany and a PhD degree (neuroscience) from University of Southern California in Los Angeles. He is a US and German dual citizen. He is fluent in English and German, with basic skills in French, Spanish and Japanese. Contact